Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 Monoclonal Antibody (mAb) GSK2849330 and Characterize Its Dose-receptor Occupancy Relationship in Subjects With Advanced HER3-Positive Solid Tumors

Next Previous
X
Search
Trial Profile

An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 Monoclonal Antibody (mAb) GSK2849330 and Characterize Its Dose-receptor Occupancy Relationship in Subjects With Advanced HER3-Positive Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 2849330 (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Diagnostic use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 16 Aug 2016 Status changed from recruiting to completed.
    • 21 Apr 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2016.
    • 21 Apr 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top